Browsing: glycemic control

Not just weight loss – Semaglutide and Cardiovascular Benefits

By 0
With the emergence and increasing popularity of glucagon-like peptide 1 (GLP-1) agonists for the treatment of obesity in recent years, it might be worth investigating if these agents are able to reduce the cardiovascular risks associated with overweight and obesity, especially since they have been shown to reduce risk of major adverse cardiovascular events in patients with type 2 diabetes who are at high cardiovascular risk.

Log In or Register as a healthcare professional to read the full article.